Clinical application of blonanserin in the treatment of schizophrenia:expert consensus from China(2024)
10.3969/j.issn.1000-6729.2025.06.14
- VernacularTitle:布南色林治疗精神分裂症临床应用中国专家建议(2024)
- Author:
Tianmei SI
1
;
Zheng LU
;
Fude YANG
;
Xiaoping WANG
;
Chuan SHI
;
Dengtang LIU
;
Yingjun ZHENG
;
Hong DENG
;
Shaohua HU
;
Xin YU
Author Information
1. 北京大学第六医院,北京大学精神卫生研究所,国家卫生健康委员会精神卫生学重点实验室(北京大学),国家精神心理疾病临床医学研究中心(北京大学第六医院),北京 100083
- Publication Type:Journal Article
- Keywords:
schizophrenia;
blonanserin;
clinical practice
- From:
Chinese Mental Health Journal
2025;39(6):561-574
- CountryChina
- Language:Chinese
-
Abstract:
Blonanserin,a second-generation atypical antipsychotic agent,acts as an antagonist for dopamine D2,D3,and serotonin 5-HT2A receptors.Clinical studies have demonstrated that blonanserin is non-inferior to other antipsychotics,such as haloperidol and risperidone,in alleviating the symptoms of schizophrenia.Moreover,it exhib-its beneficial effects on cognitive symptoms and social functioning,with a favorable safety profile,making it one of the key treatment options for schizophrenia.With extensive clinical experience accumulated in China,this expert consensus aims to provide psychiatrists with updated and localized guidance on the optimal use of blonan-serin.Based on a systematic review of the latest evidence-particularly studies in Chinese population,this paper pres-ents the updated Chinese expert recommendations for the clinical use of blonanserin in 2024.
